HS
PVLA

HighVista Strategies’s Palvella Therapeutics PVLA Stock Holding History

HighVista Strategies’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,903
Closed -$736K – 184
2026
Q1 		$736K Buy
+5,903
New +$616K 0.2% 131
2020
Q3 		– Sell
-335
Closed -$83K – 133
2020
Q2 		$83K Buy
335
+101
+43% +$23.6K 0.07% 79
2020
Q1 		$43K Hold
234
– – 0.04% 51
2019
Q4 		$68K Buy
234
+85
+57% +$23.6K 0.05% 106
2019
Q3 		$41K Buy
+149
New +$57.7K 0.03% 126

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

HighVista Strategies's PVLA Position: Q2 2026 in Review

HighVista Strategies sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 5,903 shares — an estimated $736K sold.

HighVista Strategies first reported a position in PVLA in Q3 2019 and held it in 5 quarters. The position peaked at $736K in Q1 2026. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • HighVista Strategies reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HighVista Strategies sold 5,903 Palvella Therapeutics shares in Q2 2026, an estimated $736K.
  • HighVista Strategies first reported a position in Palvella Therapeutics in Q3 2019 and held it in 5 quarters.
  • HighVista Strategies's Palvella Therapeutics position peaked at $736K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.